Alexander Gutin
Overview
Explore the profile of Alexander Gutin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
5613
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kurian A, Hughes E, Simmons T, Bernhisel R, Probst B, Meek S, et al.
Cancer
. 2021 Jul;
127(20):3742-3750.
PMID: 34228814
Background: The IBIS/Tyrer-Cuzick model is used clinically to guide breast cancer screening and prevention, but was developed primarily in non-Hispanic White women. Little is known about its long-term performance in...
12.
Hughes E, Tshiaba P, Wagner S, Judkins T, Rosenthal E, Roa B, et al.
JCO Precis Oncol
. 2021 May;
5.
PMID: 34036224
Purpose: Screening and prevention decisions for women at increased risk of developing breast cancer depend on genetic and clinical factors to estimate risk and select appropriate interventions. Integration of polygenic...
13.
Rothschild A, Parikh S, Hain D, Law R, Thase M, Dunlop B, et al.
Psychiatry Res
. 2020 Dec;
296:113649.
PMID: 33360967
We evaluated the clinical validity of a combinatorial pharmacogenomic test and single-gene Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines against patient outcomes and medication blood levels to assess their ability to...
14.
Curtis J, Xie F, Crowson C, Sasso E, Hitraya E, Chin C, et al.
Arthritis Res Ther
. 2020 Dec;
22(1):282.
PMID: 33276814
Background: Rheumatoid arthritis (RA) patients have increased risk for cardiovascular disease (CVD). Accurate CVD risk prediction could improve care for RA patients. Our goal is to develop and validate a...
15.
Hughes E, Tshiaba P, Gallagher S, Wagner S, Judkins T, Roa B, et al.
JCO Precis Oncol
. 2020 Sep;
4.
PMID: 32923876
Purpose: Women with a family history of breast cancer are frequently referred for hereditary cancer genetic testing, yet < 10% are found to have pathogenic variants in known breast cancer...
16.
Soliman H, Flake 2nd D, Magliocco A, Robson M, Schwartzberg L, Sharma P, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914026
Purpose: Previous studies have shown EndoPredict (EPclin), a test that integrates 12-gene expression data with nodal status and tumor size, to be predictive for risk of distant recurrence in women...
17.
Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa B, et al.
JAMA Netw Open
. 2020 Jul;
3(7):e208501.
PMID: 32609350
Importance: To date, few studies have examined the extent to which polygenic single-nucleotide variation (SNV) (formerly single-nucleotide polymorphism) scores modify risk for carriers of pathogenic variants (PVs) in breast cancer...
18.
Soliman H, Wagner S, Flake 2nd D, Robson M, Schwartzberg L, Sharma P, et al.
Ann Surg Oncol
. 2020 Jan;
27(3):765-771.
PMID: 31907749
Background: Neo-adjuvant chemotherapy (NaCT) facilitates complete surgical resection in locally advanced breast cancer. Due to its association with improved outcome, complete pathologic response (pCR) to neo-adjuvant treatment has been accepted...
19.
Curtis J, Flake D, Weinblatt M, Shadick N, Ostergaard M, Hetland M, et al.
Rheumatology (Oxford)
. 2018 Dec;
58(5):874-883.
PMID: 30590790
Objective: To develop and evaluate an adjusted score for the multi-biomarker disease activity (MBDA) test to account for the effects of age, sex and adiposity in patients with RA. Methods:...
20.
Hodgson D, Dougherty B, Lai Z, Fielding A, Grinsted L, Spencer S, et al.
Br J Cancer
. 2018 Oct;
119(11):1401-1409.
PMID: 30353044
Background: Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2....